Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals

Acta Pharmaceutica

Volumn 59, Issue 1, 2009, Pages 67-73

  El Shazly, Amany Hassan M ^a   Mahmoud, Atef Mohamed ^a   Darwish, Nevine Salah ^a  

^a Institute of Ophthalmology   (Egypt)

Author keywords

Aminoguanidine; Antioxidants; Diabetic retinopathy; Glycated end product; Nephropathy; Nitric oxide

Indexed keywords

AMINOGUANIDINE; CATALASE; GLUCOSE; GLUTATHIONE PEROXIDASE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY; MALE; NONHUMAN; PROPHYLAXIS; RAT; RETINA; STREPTOZOCIN DIABETES; WISTAR RAT;

EID: 63149128708     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10007-009-0009-8     Document Type: Article

References (16)

1. A. W. Stitt, Advanced glycation: an important pathological event in diabetic and age related ocular disease, Br. J. Opthalmol. 25 (92001) 746-753; DOI: 10.1136/bjo.85.6.746.
2. A. W. Stitt, T. Bahduri, C. B. McMullen, T. A. Gardinger and D. B. Archer, Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats, Mol. Cell. Biol. Res. Commun. 3 (2000) 380-88; DOI: 10.1006/mcbr.2000.0243.
3. J. M. Hughes, E. G. Kuiper, I. Klaassen, P. Canning, A. W. Stitt and J. Vanbezo, Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina, Diabetologia 50 (2007) 1089-1098; DOI: 10.1007/s00125-007-0621-4.
4. H. Noh, K. H. Choi, D. S. Han and H. Y. Lee, High glucose increases inducible NO production in cultured rat mesengial cells. Possible role in fibronectin production, Nephron. 90 (2002) 78-85.
5. S. S. Ahanchi, V. N. Varu, N. D. Tsihlis, J. Martinez, C. G. Pearce, M. R. Kapadia, Q. Jiang, J. E. Saavedra, L. K. Keefer, J. A. Hrabie and M. R. Kibbe, Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome, Am. J. Physiol. Heart. Circ. Physiol. 295 (2008) 2388-2398.
6. G. P. Bautista, L. G. Sanchez, C. U. Cristobal, E. Tapia, V. Soto and C. M. Avila, Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-beta 1 over expression in 5/6 neprhectomized rats, Nephrol. Diab. Transpl. 21 (2006) 3074-3081.
7. H. J. Han, J. L. Lee, S. H. Park, J. H. Lee and M. Taub, High glucose induced oxidative stress inhibits Na/glucose transporter activity in renal proximal tubule cells, Am. J. Physiol. Renal Physiol. 288 (2004) F988-F998; DOI: 10.1152/ajprenal.00327.2004.
8. M. C. Thomas, H. U. Forbes and M. E. Cooper, Advanced glycation end products and diabetic nephropathy, Am. J. Ther. 12 (2005) S62-S72; DOI: 10.1097/01.mjt.0000178769.52610.69.
9. S. Varsan, P. Foiles and H. Founds, Therapeutic potential of breakers of advanced glycation end product-protein cross links, Arch. Biochem. Biophys. 419 (2003) 89-96.
10. V. Brodiak and N. O. Sybirua, Effect of aminoguanidine on oxidative modification of proteins in experimental diabetes mellitus in rats, Ukr. Biochim. Zh. 78 (2006) 114-119.
11. O. Azal, A. Yohem, B. Cakir, A. Baydar, A. Corakei and M. Kutli, Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats, Diabetes Obes. Metab. 4 (2002) 75-79; DOI: 10.1046/j.1463-1326.2002.00182.x.
12. G. R. Stoppa, M. Cesquini, E. A. Roma, S. H. Ogo and M. A. Torsoni, Aminoguanidine prevented impairment of blood antioxidant system in insulin dependent diabetic rats, Life Sci. 78 (2006) 1352-1361; DOI: 10.1016 /j.lfs. 2005.07.031.
13. L. Zheng, B. Gong, D. A. Hatala and T. S. Kern, Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes, Invest. Ophth. Vis. Sci. 48 (2007) 361-367; DOI: 10.1167/ iovs.06-0510.
14. D. J. Kelly, R. E. Gilbert, A. J. Cox, T. Soulis, G. Jerums and M. E. Cooper, Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy, J. Am. Soc. Nephrol. 12 (2001) 2098-2107.
15. H. Sugimoto, G. Grahovac, M. Zeisberg and R. Kalluri, Renal fibrosis and glumerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors, Diabetes 56 (2007) 1825-1833.
16. O. Adbelzaher, M. M. Adbelrahman, M. M. Hafez and F. M. Omran, Role of nitric oxide and reduced glutathione in the protective effects of aminoguanidine, gadolinium chloride and oleanolic acid against acetaminophen-induced hepatic and renal damage, Toxicology 234 (2007) 124-134.